Full Breakdown
Trump Administration Reclassifies Medical Marijuana to Schedule III
4/24/2026, 2:32:44 AM
Major Policy Shift in Marijuana Classification
On April 23, 2026, Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This significant change, directed by President Donald Trump, aims to ease regulations surrounding medical marijuana, which has long been classified alongside drugs like heroin and LSD. The new classification allows for greater research opportunities and provides tax benefits to licensed medical marijuana operators, marking a pivotal moment in U.S. drug policy.
Details of the Reclassification
The reclassification means that products containing marijuana approved by the Food and Drug Administration (FDA) or licensed for medical use by states will now face less stringent regulations. Schedule III drugs, which include substances like ketamine and anabolic steroids, are considered to have a moderate potential for abuse compared to Schedule I drugs. Blanche stated, “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”
The order also initiates an expedited hearing process set for June 29, 2026, to evaluate broader changes to marijuana's federal status. This move aligns with Trump's December 2025 executive order aimed at enhancing medical marijuana research.
Implications for Medical Marijuana Programs
The reclassification legitimizes medical marijuana programs in the 40 states that have adopted them, creating a streamlined process for state-licensed producers to register with the Drug Enforcement Administration (DEA). Additionally, it clarifies that researchers will not face penalties for using state-licensed marijuana in their studies. However, marijuana remains illegal at the federal level, and the reclassification does not legalize its recreational use.
Criticism and Opposition
Despite the advancements, not all Republicans support the reclassification. Rep. Andy Harris (R-MD), chairman of the Freedom Caucus, expressed concerns that the move could expose youth to an addictive substance. Critics like Kevin Sabet, CEO of Smart Approaches to Marijuana, argue that the administration's actions send a confusing message about marijuana's risks and advocate for alternative methods to promote research without easing regulations.
Broader Context and Future Considerations
The reclassification comes amid a growing trend of state-level legalization, with 24 states and Washington, D.C., allowing recreational use and 38 states permitting medical use. The Biden administration had previously initiated a review of marijuana's classification, but the process was not finalized. The Trump administration's order represents a significant shift in federal policy, reflecting changing public attitudes toward cannabis.
As the June hearing approaches, stakeholders in the cannabis industry and advocacy groups are closely monitoring developments, hoping for further reforms that could lead to full legalization. Morgan Fox of the National Organization for the Reform of Marijuana Laws noted that while the reclassification is a step forward, the ultimate goal remains the complete descheduling of cannabis at the federal level.
Verbatim Quotes
- “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” — Todd Blanche, Acting Attorney General
- “We don’t need rescheduling to do medical research on marijuana–all we are doing is exposing more of our youth to an addictive drug.” — Rep. Andy Harris (R-MD)
- “Moving it out of that classification allows us to have policy conversations that don't start and end with that definition,” — Morgan Fox, National Organization for the Reform of Marijuana Laws
Conclusion
The Trump administration's reclassification of medical marijuana to Schedule III marks a significant shift in federal drug policy, facilitating research and easing regulatory burdens for state-licensed operators. While the move has garnered both support and criticism, it reflects a broader trend toward reevaluating cannabis's role in American healthcare and society. The upcoming hearing in June will be crucial in determining the future trajectory of marijuana policy in the United States.
